BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29553749)

  • 21. Drug and gene co-delivery systems for cancer treatment.
    Yang Z; Gao D; Cao Z; Zhang C; Cheng D; Liu J; Shuai X
    Biomater Sci; 2015 Jul; 3(7):1035-49. PubMed ID: 26221938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug targeting systems for cancer therapy: nanotechnological approach.
    Tigli Aydin RS
    Mini Rev Med Chem; 2015; 14(13):1048-54. PubMed ID: 25138089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanodrugs used in cancer therapy.
    Kopeckova K; Eckschlager T; Sirc J; Hobzova R; Plch J; Hrabeta J; Michalek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Jun; 163(2):122-131. PubMed ID: 30967685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
    Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
    Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy.
    Andresen TL; Thompson DH; Kaasgaard T
    Mol Membr Biol; 2010 Oct; 27(7):353-63. PubMed ID: 20939771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
    Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
    Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications.
    Saadh MJ; Mustafa MA; Kumar A; Alamir HTA; Kumar A; Khudair SA; Faisal A; Alubiady MHS; Jalal SS; Shafik SS; Ahmad I; Khry FAF; Abosaoda MK
    AAPS PharmSciTech; 2024 Jun; 25(6):140. PubMed ID: 38890191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.
    Mignani S; Bryszewska M; Klajnert-Maculewicz B; Zablocka M; Majoral JP
    Biomacromolecules; 2015 Jan; 16(1):1-27. PubMed ID: 25426779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent progress in drug delivery systems for anticancer agents.
    Kim CK; Lim SJ
    Arch Pharm Res; 2002 Jun; 25(3):229-39. PubMed ID: 12135091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy.
    Shen S; Liu M; Li T; Lin S; Mo R
    Biomater Sci; 2017 Jul; 5(8):1367-1381. PubMed ID: 28664207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal therapies in oncology: does one size fit all?
    Sousa I; Rodrigues F; Prazeres H; Lima RT; Soares P
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):741-755. PubMed ID: 30116847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomedicine: a new frontier in cancer therapeutics.
    Lee PY; Wong KK
    Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
    Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO
    Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
    Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanomaterial-Enabled Cancer Therapy.
    Quader S; Kataoka K
    Mol Ther; 2017 Jul; 25(7):1501-1513. PubMed ID: 28532763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. pH-sensitive nano-systems for drug delivery in cancer therapy.
    Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
    Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Light-induced liposomes for cancer therapeutics.
    Chen W; Goldys EM; Deng W
    Prog Lipid Res; 2020 Jul; 79():101052. PubMed ID: 32679153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of nanomedicine mechanical properties on tumor targeting delivery.
    Li Z; Xiao C; Yong T; Li Z; Gan L; Yang X
    Chem Soc Rev; 2020 Apr; 49(8):2273-2290. PubMed ID: 32215407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.